Novartis and The Max Foundation Transform Pioneering Cancer Access Program for People in Lower-Income Countries
The Max Foundation to lead program for patients and oversee supply chain management; Novartis to contribute funding and product donation.
Novartis announced a new collaboration with The Max Foundation to support continued access to treatment at no cost for nearly 34,000 current patients with chronic myeloid leukemia (CML), gastrointestinal tumors (GIST) and other rare cancers. The two organizations have been long-time collaborators in providing access to care for patients in lower-income countries through the Glivec International Patient Assistance Program (GIPAP), one of the most innovative patient assistance programs ever implemented on a global scale.
Novartis Foundation and its partners, including Intel Corporation, the NCD Alliance, city governments and local partners, announce the launch of Better Hearts Better Cities.
On World Hypertension Day 2017, the Novartis Foundation and its partners, including Intel Corporation, the NCD Alliance, city governments and local partners, announce the launch of Better Hearts Better Cities, an innovative initiative to address the high rates of high blood pressure (hypertension) in low-income urban communities.
Leaders from Novartis, Sodexo, Johnson & Johnson and Marriott International provide insights into critical factors that enabled their companies to make progress in gender balance in senior leadership.
Novartis, J&J, Marriott and Sodexo have made significant progress in increasing women representation in senior leadership. Four years ago, these four companies, on average, had 13% and 6% more women in levels 2 and 3, respectively (one and two levels below CEO and direct reports), than the Top 50. Now, they have 25% and 36% more women in those levels than the Top 50.
This panel discussion from the 2017 DiversityInc Top 50 Learning Sessions will give you insights into critical factors that enabled these companies to make progress in gender balance in senior leadership.
• Caryn Parlavecchio, Head of HR and US Country Head HR, Novartis Pharmaceuticals Corporation
• Wanda Hope, Chief Diversity Officer, Johnson & Johnson
• Marisa Milton, Regional VP Human Resources, Marriott International
• Moderator: Sandy Harris, Vice President, Global Diversity & Inclusion, Sodexo
Meet some of the faces behind the Novartis Malaria Initiative and listen to their stories.
"We have much to gain from Dr. Narasimhan's leadership in both global health and in drug development at Novartis," said Head of the Novartis Foundation Ann Aerts.
The Novartis Foundation (No. 2 on the DiversityInc Top 50 Companies list) announced on March 23 that Vasant (Vas) Narasimhan, M.D., joined its Board of Trustees in January. He replaces Rainer Boehm, who stepped down from the Board upon his retirement as Chief Commercial and Medical Affairs Officer for Novartis Pharma AG.
Dr. Narasimhan has been Global Head of Drug Development and Chief Medical Officer for Novartis since February 1, 2016, and is a member of the Executive Committee of Novartis. He brings to the Foundation a wide range of leadership experience in Novartis development and commercial functions, spanning general medicines, oncology, biosimilars and vaccines. Before joining Novartis in 2005, he worked extensively on global public health issues, including HIV/AIDS treatment, multi-drug resistant tuberculosis, and public health policy.
Dr. Narasimhan earned his medical degree from Harvard Medical School, a master's degree in public policy from Harvard's John F. Kennedy School of Government and a bachelor's degree in biological sciences from the University of Chicago, all in the US. He is also an elected member of the (US) National Academy of Medicine.
"I am very excited to have Vas Narasimhan join us on the Board," says Ann Aerts, Head of the Novartis Foundation. "At the Novartis Foundation, we strive to have unparalleled impact on the health of low- to middle-income communities through a combination of programmatic work, outcomes research, and its translation into policy to tackle emerging global health challenges. We have much to gain from Dr. Narasimhan's leadership in both global health and in drug development at Novartis, particularly the unprecedented rise and risk of non-communicable diseases and evolving ways to address them."
Vas Narasimhan welcomes the new opportunity: "I share the foundation's commitment to innovation in healthcare delivery. Advances in medicine and public health too often leave the poorest populations behind. Bridging interventions in public health, healthcare systems and clinical practice, the Novartis Foundation is uniquely positioned to reach the most underserved patients together with its local and global partners. I look forward to supporting its efforts to have a transformational impact on people's lives, no matter where they live."
The Novartis Foundation thanks outgoing Board member Rainer Boehm for his contributions as part of the Novartis Foundation Board of Trustees over the past two years and wishes him a happy and long retirement.
Novartis enters into an exclusive option agreement with Ionis and Akcea to license two investigational treatments expected to reduce cardiovascular risk in patients living with elevated levels of lipoprotein.
Novartis (No. 2 on the DiversityInc Top 50 Companies list) has announced a collaboration and option agreement with Ionis Pharmaceuticals, Inc. and its affiliate Akcea Therapeutics, Inc., to license two novel treatments with the potential to significantly reduce cardiovascular risk in patients suffering from high levels of lipoproteins known as Lp(a) and ApoCIII.
The results of the sickle cell study are being published in The New England Journal of Medicine.
Results from the Phase II SUSTAIN study show that SEG101 (crizanlizumab, formerly SelG1), an anti-P-selectin antibody, reduced the median annual rate of sickle cell-related pain crises (SCPC) by 45.3 percent compared to placebo (1.63 vs 2.98, p=0.010) in patients with or without hydroxyurea therapy1.
Novartis Acquires Selexys Pharmaceuticals Corporation, SelG1 Antibody for Pain Reduction in Sickle Cell Disease
Acquisition complements and broadens Novartis' hematology pipeline and underscores commitment to improving care for patients with high unmet needs.
Compound offers a potential tool for fighting drug-resistant malaria parasites.
In a remote village in Thailand, on the border of Myanmar (formerly Burma), Novartis (No. 2 on the DiversityInc Top 50 Companies list) researchers completed an early-phase clinical trial of an experimental treatment for malaria. The team overcame floods that swamped the facility — an open-air structure with wooden beds and a folding table for a pharmacy — to test a compound called KAF156 in adults with the disease.
The event will take place November 29 on the Novartis Campus in Basel, Switzerland and will also be webcast.
Meet Novartis' flying hospital that brings training to local eye care professionals in under-resourced communities
In the 10 years Zhang Bin has been an ophthalmologist, he's performed hundreds of cataract surgeries. Yet he saw there was still tremendous need for improved access to eye care among the 8 million people living in and around Shenyang, where some of his patients travel three hours for treatment.
Novel Novartis Malaria Compound Shows Potential to be Effective Against Infections Resistant to Antimalarial Drugs
Each year, malaria kills nearly half a million people, most of whom are children.
Novartis (No. 2 on the DiversityInc Top 50 Companies list) published proof of concept study results in the New England Journal of Medicine showing that its new antimalarial compound, KAF156, demonstrated activity against both vivax and falciparum malaria, including artemisinin-resistant parasites. Malaria is a life-threatening disease primarily caused by parasites (Plasmodium falciparum andPlasmodium vivax) transmitted to people through the bites of infected Anopheles mosquitos.